Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24

Articles

173342 items
12:00 AM, Dec 05, 1994  |  BC Week In Review | Company News  |  Deals

TheraTech deal

THRT will receive fees and milestones totaling several million dollars and will retain manufacturing rights. The agreement also grants THRT future co-promotion rights in certain of the markets, after a period of exclusivity for SmithKline....
12:00 AM, Dec 05, 1994  |  BC Week In Review | Company News  |  Deals

MGI deal

MGI Pharma Inc. (MOGN)   The Upjohn Co. of Canada received exclusive marketing rights in Canada to MOGN's Salagen Tablets, which treat radiation-induced dry mouth in head and neck cancer patients. Upjohn is responsible for...
12:00 AM, Dec 05, 1994  |  BC Week In Review | Clinical News  |  Regulatory

U.S. Bioscience regulatory update

Separately, UBS received notice of allowance for a U.S. patent covering a form of crystalline amifostine and a method for manufacturing crystalline amifostine. The form of amifostine covered by the patent is not the subject...
12:00 AM, Dec 05, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Andrx Pharmaceuticals Inc. regulatory update

The Fort Lauderdale, Fla., company received a Notice of Allowance for a patent covering its Peletab drug delivery system. The system uses polymer coated pellets that are manufactured into tablets for extended drug delivery. Peletab...
12:00 AM, Dec 05, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Advanced Polymer regulatory update

Advanced Polymer Systems Inc. (APOS)   APOS's NDA for ProZone sunscreen has been accepted for review by the FDA, the Redwood City, Calif., company said. ProZone uses APOS's Microsponge delivery system with color-modified melanin.   ...
12:00 AM, Dec 05, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Cangene Corp regulatory update

CNJ received Australian Patent No. 647,411, covering an enhanced version of its nucleic acid sequence based amplification (NASBA) technology. NASBA detects disease and microbial contamination by targeting the nucleic acid present in a biological sample....
12:00 AM, Dec 05, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Amgen regulatory update

Amgen Inc. (AMGN)   The European Patent Office Technical Board of Appeals upheld the original DNA and process claims of Kirin-Amgen's European patent number 148605 for recombinant erythropoietin. The board also accepted modified claims on the...
12:00 AM, Dec 05, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Ethical regulatory update

The Godmanchester, U.K., company received U.K. approval to market its transdermal estrogen patch for the treatment of menopausal symptoms. A launch is planned for the first half of 1995 by an undisclosed licensee. Ethical Holdings...
12:00 AM, Dec 05, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Cytogen regulatory update

CYTO (Princeton, N.J.) said it will submit an NDA for Samarium EDTMP, a treatment for the pain associated with bone metastases, in the first half of 1995. CYTO had expected to file prior to the...
12:00 AM, Dec 05, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Chiron, Murex regulatory update

The High Court of Justice for England and Wales granted a permanent injuction against the manufacture and sale of hepatitis C virus (HCV) immunoassays by Murex Diagnostics Ltd., a unit of MXX, and Organon Teknika...

Pages